The immune checkpoint regulator CD40 potentiates myocardial inflammation

Area of Science:

• Immunology
• Cardiology
• Oncology

Background:

• Immune checkpoint therapies, including CD40 agonists, show promise for treating resistant cancers.
• Conventional inhibitors (PD-1, PD-L1, CTLA-4) can cause severe cardiac adverse events like myocarditis.
• The cardiac risks associated with CD40 agonists are largely unknown.

Purpose of the Study:

• To investigate the potential of CD40 agonists to induce myocardial inflammation and myocarditis.
• To elucidate the mechanisms by which CD40 agonists affect the cardiac immune environment.

Main Methods:

• Utilized genetic mouse models.
• Employed single-cell sequencing.
• Conducted cell depletion studies.

Main Results:

• Anti-CD40 agonist antibody reshaped the cardiac immune landscape via CCR2+ macrophage activation.
• Demonstrated recruitment of effector memory CD8+ T cells.
• Identified a positive feedback loop involving CCR2+ macrophages and CD8+ T cells (IL-12b, TNF, IFNγ signaling) promoting inflammation.
• Showed prior CD40 agonist exposure sensitizes the heart to secondary insults and accelerates left ventricular remodeling.

Conclusions:

• CD40 agonists can promote myocardial inflammation through macrophage and T cell activation.
• These findings suggest a potential mechanism for CD40 agonists to exacerbate heart failure pathogenesis.
• Highlights the need for careful cardiac monitoring during CD40 agonist therapy.